Here we show that pharmacologic inhibition of heat shock protein 90 (HSP90) with a small-molecule inhibitor, NVP-AUY922 (AUY922), leads to rapid degradation of TYK2 and apoptosis in T-ALL cells.

A major advantage of targeting Hsp90 is that its inhibition can lead to the degradation of multiple different cancer-causing proteins by the cell’s garbage-disposal system. This gives Hsp90 inhibitors ...

To test this, the researchers injected the Hsp90 inhibitor KU-32 into the spinal cord of mice prior to morphine treatment and then exposed the animals to the tail-flick test, an established pain model ...

Hsp90 signaling and its inhibition in cancer The evaluation of Hsp90 as a therapeutic target in cancer patients is another major focus of our lab. Hsp90 is a chaperone required for maintaining the ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

The Chiosis Laboratory has demonstrated the efficacy of PU-H71, an Hsp90 inhibitor currently in Phase I clinical trials, in a wide array of cancers (breast cancer, pancreatic cancer, leukemia, ...

Prof Timothy Street and student Tara Azam are investigating Hsp90 inhibitors as potential cancer treatments. Hsp90 is crucial for many cancer-causing proteins, making it a target for anti-cancer drugs ...

In the talk, Sanil Bhatia moved from the function of HSP90 in cancer cells to inhibitors that target HSP90. He highlighted inhibitors that target the dimerization of HSP90 as these are designed to ...